405 related articles for article (PubMed ID: 16044276)
1. Long-term serial echocardiographic examination of late anthracycline cardiotoxicity and its prevention by dexrazoxane in paediatric patients.
Elbl L; Hrstkova H; Tomaskova I; Blazek B; Michalek J
Eur J Pediatr; 2005 Nov; 164(11):678-84. PubMed ID: 16044276
[TBL] [Abstract][Full Text] [Related]
2. Late anthracycline cardiotoxicity protection by dexrazoxane (ICRF-187) in pediatric patients: echocardiographic follow-up.
Elbl L; Hrstkova H; Tomaskova I; Michalek J
Support Care Cancer; 2006 Feb; 14(2):128-36. PubMed ID: 16034614
[TBL] [Abstract][Full Text] [Related]
3. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
Seymour L; Bramwell V; Moran LA
Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
[TBL] [Abstract][Full Text] [Related]
4. Cardioprotective effect of early dexrazoxane use in anthracycline treated pediatric patients.
Kang M; Kim KI; Song YC; Shin WG; Oh JM
J Chemother; 2012 Oct; 24(5):292-6. PubMed ID: 23182049
[TBL] [Abstract][Full Text] [Related]
5. The effect of dexrazoxane for clinical and subclinical cardiotoxicity in children with acute myeloid leukemia.
Sánchez-Medina J; Gonzalez-Ramella O; Gallegos-Castorena S
J Pediatr Hematol Oncol; 2010 May; 32(4):294-7. PubMed ID: 20404753
[TBL] [Abstract][Full Text] [Related]
6. Dexrazoxane : a review of its use for cardioprotection during anthracycline chemotherapy.
Cvetković RS; Scott LJ
Drugs; 2005; 65(7):1005-24. PubMed ID: 15892593
[TBL] [Abstract][Full Text] [Related]
7. [Monitoring cardiotoxicity of anthracyclines in children and possibilities of its prevention].
Sromová T; Strnadová V; Hrstková H
Vnitr Lek; 2002 Jul; 48(7):649-56. PubMed ID: 12197409
[TBL] [Abstract][Full Text] [Related]
8. Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy.
Wiseman LR; Spencer CM
Drugs; 1998 Sep; 56(3):385-403. PubMed ID: 9777314
[TBL] [Abstract][Full Text] [Related]
9. Dexrazoxane for preventing anthracycline cardiotoxicity in children with solid tumors.
Choi HS; Park ES; Kang HJ; Shin HY; Noh CI; Yun YS; Ahn HS; Choi JY
J Korean Med Sci; 2010 Sep; 25(9):1336-42. PubMed ID: 20808678
[TBL] [Abstract][Full Text] [Related]
10. Subclinical anthracycline-induced cardiotoxicity in long-term follow-up of asymptomatic childhood cancer survivors: Assessment by speckle tracking echocardiography.
Çetin S; Babaoğlu K; Başar EZ; Deveci M; Çorapçıoğlu F
Echocardiography; 2018 Feb; 35(2):234-240. PubMed ID: 29106752
[TBL] [Abstract][Full Text] [Related]
11. Exposure to anthracyclines during childhood causes cardiac injury.
Lipshultz SE
Semin Oncol; 2006 Jun; 33(3 Suppl 8):S8-14. PubMed ID: 16781284
[TBL] [Abstract][Full Text] [Related]
12. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial.
Lipshultz SE; Scully RE; Lipsitz SR; Sallan SE; Silverman LB; Miller TL; Barry EV; Asselin BL; Athale U; Clavell LA; Larsen E; Moghrabi A; Samson Y; Michon B; Schorin MA; Cohen HJ; Neuberg DS; Orav EJ; Colan SD
Lancet Oncol; 2010 Oct; 11(10):950-61. PubMed ID: 20850381
[TBL] [Abstract][Full Text] [Related]
13. Use of ICRF-187 for prevention of anthracycline cardiotoxicity in children: preliminary results.
Schiavetti A; Castello MA; Versacci P; Varrasso G; Padula A; Ventriglia F; Werner B; Colloridi V
Pediatr Hematol Oncol; 1997; 14(3):213-22. PubMed ID: 9185206
[TBL] [Abstract][Full Text] [Related]
14. Dynamic stress echocardiography in asymptomatic patients who received chemotherapy in childhood because of a malignant disease.
Elbl L; Hrstkova H; Chaloupka V; Michalek J
Kardiol Pol; 2003 Mar; 58(3):190-6. PubMed ID: 14513093
[TBL] [Abstract][Full Text] [Related]
15. Cardioprotective effect of dexrazoxane in patients with breast cancer treated with anthracyclines in adjuvant setting: a 10-year single institution experience.
Testore F; Milanese S; Ceste M; de Conciliis E; Parello G; Lanfranco C; Manfredi R; Ferrero G; Simoni C; Miglietta L; Ferro S; Giaretto L; Bosso G
Am J Cardiovasc Drugs; 2008; 8(4):257-63. PubMed ID: 18690759
[TBL] [Abstract][Full Text] [Related]
16. Dexrazoxane for the prevention of cardiomyopathy in anthracycline treated pediatric cancer patients.
Anderson B
Pediatr Blood Cancer; 2005 Jun; 44(7):584-8. PubMed ID: 15700251
[TBL] [Abstract][Full Text] [Related]
17. Ameliorating anthracycline cardiotoxicity in children with cancer: clinical trials with dexrazoxane.
Wexler LH
Semin Oncol; 1998 Aug; 25(4 Suppl 10):86-92. PubMed ID: 9768829
[TBL] [Abstract][Full Text] [Related]
18. [Dexrazoxane in anthracycline induced cardiotoxicity and extravasation].
Goey AK; Schellens JH; Beijnen JH; Huitema AD
Ned Tijdschr Geneeskd; 2010; 154():A1155. PubMed ID: 20619024
[TBL] [Abstract][Full Text] [Related]
19. European trials with dexrazoxane in amelioration of doxorubicin and epirubicin-induced cardiotoxicity.
Lopez M; Vici P
Semin Oncol; 1998 Aug; 25(4 Suppl 10):55-60. PubMed ID: 9768825
[TBL] [Abstract][Full Text] [Related]
20. Left ventricular systolic function assessed by echocardiography in children and adolescents with osteosarcoma treated with doxorubicin alone or in combination with dexrazoxane.
de Matos Neto RP; Petrilli AS; Silva CM; Campos Filho O; Oporto VM; Gomes Lde F; Paiva MG; Carvalho AC; Moisés VA
Arq Bras Cardiol; 2006 Dec; 87(6):763-71. PubMed ID: 17262115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
